信息
- 2 粉丝
- 4 关注
- 0 歌曲
- 男
- 分享链接
- Bio
-
More recently, Malkin et al. reported a 24% prevalence of biochemical T deficiency (using either total or bioavailable T concentrations) among men with coronary disease. In this article, we review newly published studies evaluating TRT in older men and explore alterations in circulating lipids as one possible mechanism whereby T might influence CVD risk. While meta-analyses of such trials suggest that TRT does not increase CVD risk, a recent randomized trial suggested that TRT might increase risk in certain clinical populations .
It is responsible for muscle mass, regulating sex drive, bone density, and also heart health. This review discusses the molecular pathways and clinical implications of T in the vascular system. At the vascular level, the key effect of T is the vasorelaxation. Federal government websites often end in .gov or .mil. An official website of the United States government
Increasing your testosterone level might also increase your red blood cell count. Asides from the regulation of sex drive and body composition, testosterone increases the red blood cell production in the body. This is called cardiac hypertrophy, and it can affect the heart’s ability to pump blood effectively and might result in other cardiovascular complications. Though testosterone can increase strength and muscle mass, too much can cause an increase in the heart’s ventricle size. This deficiency increases the danger of cardiovascular disease and mortality. Testosterone deficiency is often linked with medical conditions like renal failure, cardiovascular diseases, malignancy, frailty, dyslipidemia, hypertension, metabolic syndrome, and diabetes. This study does not address testosterone’s safety in otherwise normal people who take it solely to build muscle or for other reasons—it just applies to patients with symptomatic hypogonadism and low testosterone levels.
Several studies have shown a correlation between low T levels and an increased prevalence of several CVD. The U.S. FDA recommends that all T supplements carry a warning that they may increase the risk of heart attack and stroke. Given emerging evidence from basic-science models, it is reasonable to assume that TRT positively affects the exercise capacity of CHF patients via a peripheral mechanism, such as promoting increased type I muscle fiber proliferation.27 Four authors have investigated the effects of TRT on exercise capacity in men with CHF.
Contrary to other reports, this study suggested that testosterone decreases the inflammatory response in mice, which may favorably affect early cardiac remodeling after MI.45,47 Rettew et al45 investigated toll‐like receptor‐4 (TLR‐4) expression in mice, as TLR‐4 has been shown to mediate various immune responses.46 In this study, macrophages were isolated from orchiectomized, sham‐orchiectomized, and orchiectomized plus testosterone‐replaced mice. All males were administered either estrogen or placebo, whereas all females were administered either testosterone or placebo. They further proposed that testosterone may compete with other vasodilatory compounds in a way that induces vasoconstriction.41 Ceballos et al did not investigate a mechanism in this study. These authors also acknowledged the previously described vasodilatory effects of testosterone. Many studies suggest that testosterone inhibits atherosclerosis,31–37 whereas some studies suggest that testosterone may be detrimental.38–39 Because of this discrepancy, more research is necessary to completely understand the association between testosterone and atherosclerosis.
In parallel, ongoing work is required to further elucidate the mechanisms by which T may influence CVD risk, including its effects on HDL and other plasma lipids. This study must be powered for CVD outcomes and, ideally, should examine TRT among a broad spectrum of hypogonadal men to stratify treatment effects by age and baseline health status, among other clinical variables. Continued research is critical to better elucidate both the effects of T on HDL composition and function and the utility of various HDL metrics in CVD risk prediction. Nonetheless, this HDL-c lowering effect has raised concern regarding the cardiovascular safety of TRT. However, the authors did not observe an association between T concentrations and HDL-c or LDL-c levels.
Furthermore, it should be noted that numerous studies have shown that high pharmacological concentrations of Tes (10–100 μM) induce vasodilation in endothelium-denuded vessels, suggesting an endothelium-independent mechanism (8, 10, 12, 24, 47, 48, 60, 63, 73). Interestingly, in studies employing small vessel wire myography, it has been reported that micromolar concentrations of Tes induce vasodilation of rat pulmonary arteries (23), human subcutaneous resistance arterioles (32), and porcine small prostatic arteries (43). This acute effect of Tes and other androgens has been observed at micromolar concentrations in a variety of large arteries (aorta, coronary and umbilical arteries) as well as small resistance arteries (mesenteric, prostatic, pulmonary, and subcutaneous) from several animal species (rat, mouse, rabbit, pig, and dog) and humans (2, 8, 10, 32, 48, 60, 71). While this effect frequently has been observed in large arteries at micromolar concentrations, more recent studies have reported vasorelaxation of smaller resistance arteries at nanomolar (physiological) concentrations. Additionally, breaking a blood vessel can result in the formation of blood clots, resulting in a life-threatening situation if the blood clot travels to the lungs or heart. Testosterone plays an essential role in the maintenance of cardiovascular health. Optimal oxygen supply to the blood vessels improves their function and health and helps combat vascular stiffness.
Furthermore, there is also the evidence that Tes produces coronary or systemic vasodilation in vivo at physiological concentrations (100 pM to 100 nM) in humans (67) and in canine and porcine animal models (3, 39). In this respect, a significant vasodilation has also been observed at physiological (low nanomolar) concentrations of Tes in rat mesenteric arterioles (64, 68) and human pulmonary resistance arteries (55) in vitro. However, it has been agreed that physiological concentrations of Tes are in the range of 100 pM–100 nM, whereas supraphysiological and pharmacological concentrations exceed 100 nM. The key mechanism underlying Tes-induced vasorelaxation appears to be the modulation of vascular smooth muscle ion channel function, particularly the inactivation of L-type voltage-operated Ca2+ channels and/or the activation of voltage-operated and Ca2+-activated K+ channels. It can damage blood vessels, resulting in internal bleeding inside the muscle during the injection. Their personalized advice can help you attain heart health and optimal hormone balance.
Although VOCC function may differ in cultured cell lines, the results in primary cultured and freshly dissociated rat aortic myocytes (41) are consistent with the findings of these reports. This possibility is supported by previous in vivo studies that demonstrated that Tes-induced vasodilation of both canine coronary and porcine systemic arteries was nitric oxide (NO) dependent (3, 39). Clearly, these data suggest the presence of an endothelium-dependent mechanism at physiological concentrations of Tes (11–36 nmol/l). In this latter study, sensitivity to Tes-induced vasodilation was much higher in endothelium-intact than in endothelium-denuded vessels (1 nM vs. 30 μM; Ref. 55). Moreover, in electrophysiological (patch clamp) experiments measuring ion currents in single VSM cells, Tes acts at nanomolar concentrations (8, 17, 41, 58, 59) and even at circulating (36 nmol/l) concentrations (17, 58, 59) to inhibit Ca2+ channels. - https://nildigitalco.com/@tonjawinfrey5?page=about
关注艺术家
